Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
2.
Exp Dermatol ; 22(4): 262-5, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23528211

ABSTRACT

Neurofibromatosis type I (NF1) is associated with typical hypervascular tumors, including neurofibroma, glioma, malignant peripheral nerve sheath tumors (MPNST) and glomus tumors. Previously, we and other groups reported that neurofibromas showed high-level expression of vascular endothelial growth factor (VEGF), a potent angiogenic factor involved in neovascularization. However, the molecular mechanism underlying the upregulation of VEGF in neurofibromas remains unclear. In this study, we examined the effects of Nf1 gene silencing on VEGF expression in Schwann cell and non-Schwann cell line and the upstream mTOR-HIF-1α - VEGF pathway in Schwann cell line. The results indicated that Nf1 gene silencing by lentiviral-mediated RNA interference resulted in elevated expression of VEGF, HIF-1α and phosphorylated mTOR at the protein level. The results obtained from Nf1 gene silencing in murine Schwann cell line analogously suggest that NF1 gene haploinsufficiency in human tumor Schwann cells may directly elicit upregulation of VEGF expression without the tumor microenvironment by activation of the mTOR-HIF-1α - VEGF pathway. We also showed that interleukin-6 is upregulated in Nf1 gene knock-down Schwann cells at the protein level.


Subject(s)
Genes, Neurofibromatosis 1 , Schwann Cells/metabolism , Vascular Endothelial Growth Factor A/metabolism , Animals , Cell Line , Gene Knockdown Techniques , Gene Silencing , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Interleukin-6/metabolism , Keratinocytes/metabolism , Mice , Neurofibromatosis 1/genetics , Neurofibromatosis 1/metabolism , Neurofibromatosis 1/pathology , Signal Transduction , TOR Serine-Threonine Kinases/metabolism , Tumor Microenvironment , Up-Regulation
4.
Arch Dermatol Res ; 305(5): 371-8, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23341029

ABSTRACT

Loricrin is a major component of the epidermal cornified cell envelope, and is expressed only in terminally differentiated keratinocytes. This cell differentiation-specific expression pattern suggests specific regulatory mechanisms for activation and suppression of loricrin gene transcription in differentiated keratinocytes. Here, we identified a regulatory element in the proximal promoter region of the loricrin gene involved in suppression of its expression in keratinocytes. A database search indicated that this sequence contained a POU transcription factor binding motif. Electrophoretic mobility shift assay revealed that Oct-1, Oct-6, and Oct-11 actually bind to the motif. Constructs with point mutations in the POU-binding motif showed increased reporter activity, indicating that the POU factors negatively regulate loricrin gene transcription. Cotransfection experiments suggested that Oct-6 and Oct-11 suppress loricrin gene transcription in a cooperative manner with AP-1 and Sp1. Furthermore, in vitro experiments indicated that the Oct-6 and Oct-11 can physically associate with both AP-1 factors and Sp1/Sp3. These findings indicate that Oct-6 and Oct-11 contribute to the regulation of loricrin gene transcription via interaction with AP-1 factors and Sp1/Sp3.


Subject(s)
Keratinocytes/metabolism , Membrane Proteins/metabolism , Octamer Transcription Factor-6/metabolism , Octamer Transcription Factors/metabolism , Sp1 Transcription Factor/metabolism , Sp3 Transcription Factor/metabolism , Transcription Factor AP-1/metabolism , Animals , Binding Sites , Cells, Cultured , Databases, Genetic , Down-Regulation , Electrophoretic Mobility Shift Assay , Genes, Reporter , Membrane Proteins/genetics , Mice , Point Mutation , Promoter Regions, Genetic , Regulatory Elements, Transcriptional , Sequence Analysis, DNA , Transcription, Genetic , Transfection
5.
J Microbiol Biotechnol ; 20(2): 375-82, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20208444

ABSTRACT

The available techniques for heterologous protein secretion in Lactobacillus strains are limited. The aim of the present study was to develop an efficient protein-secretion system using recombinant lactobacilli for various applications such as live delivery of biotherapeutics. For the construction of expression vectors, the Lactobacillus brevis slpA promoter, Lactobacillus casei prtP signal sequence, and mouse IL-10 sequences were used as a model system. Interestingly, the slpA promoter exhibited strong activity in L. casei contrary to previous observations. In order to stabilize replication of the plasmid in E. coli, a removable terminator sequence was built into the promoter region. For the improvement of secretion efficiency, a DTNSD oligopeptide was added to the cleavage site of signal peptidase. The resulting plasmids provided remarkably efficient IL-10 secretion. Accumulation of the protein in the culture supernatant varied widely according to the pH conditions. By analysis of the secreted protein, formation of homodimers and biological activity, IL-10 was confirmed to be functional. The presently constructed plasmids could be useful tools for heterologous protein-secretion in L. casei.


Subject(s)
Extracellular Space/metabolism , Interleukin-10/genetics , Interleukin-10/metabolism , Lacticaseibacillus casei/genetics , Protein Engineering/methods , Animals , Base Sequence , Extracellular Space/genetics , Genetic Vectors/genetics , Genetic Vectors/metabolism , Lacticaseibacillus casei/metabolism , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Plasmids/genetics , Plasmids/metabolism , Protein Transport
6.
J Am Acad Dermatol ; 55(5 Suppl): S81-5, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17052540

ABSTRACT

Recently, low-dose 5-fluorouracil/cisplatin induction concurrent with radiation (chemoradiation) has been reported to be effective for locally advanced squamous cell carcinoma of the otorhinolaryngologic and gynecologic regions. However, to date, this therapeutic option has not been evaluated for squamous cell carcinoma of the skin. We evaluated chemoradiation therapy using cisplatin and 5-fluorouracil in two patients with locally advanced squamous cell carcinoma of the skin. Administration of cisplatin and 5-fluorouracil was conducted concurrently with conventionally fractionated radiation therapy. Cisplatin (patient 1: 4 mg/m(2)/d on days 1 to 5; patient 2: 15 mg/m(2)/d on days 1 to 5) and 5-fluorouracil (patient 1: 400 mg/m(2)/d for 7 days; patient 2: 850 mg/m(2)/d for 5 days) were administered intravenously for 1 hour and for 24 hours, respectively. Patient 1 underwent two courses of chemotherapy with a 3-week interval, and patient 2 underwent a single course of chemotherapy. The primary tumor of both patients showed complete regression, leaving ulceration. In patient 1, the ulceration completely resolved after 3 months. Patient 2 underwent surgical resection and full-thickness skin grafting. A histopathologic examination confirmed complete tumor regression. Neither patient suffered any serious side effects during this treatment. We conclude that chemoradiation using cisplatin and 5-fluorouracil was effective in these two patients with locally advanced squamous cell carcinoma of the skin. Several randomized studies have shown concurrent chemoradiation to be superior to radiation alone. This regimen is an option in managing patients who have unresectable primary tumors or who require preservation of local function.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/radiotherapy , Skin Neoplasms/drug therapy , Skin Neoplasms/radiotherapy , Aged , Cisplatin/administration & dosage , Combined Modality Therapy , Female , Fluorouracil/administration & dosage , Humans , Male , Middle Aged , Treatment Outcome
7.
Bioorg Med Chem Lett ; 15(4): 1111-4, 2005 Feb 15.
Article in English | MEDLINE | ID: mdl-15686923

ABSTRACT

Suppression of resistance to anticancer drugs by COTC of glyoxalase I (GloI) inhibitor targeting intracellular glutathione (GSH) and GloI was studied. Depletion of the cellular GSH content and inhibition of GloI by COTC increased chemotherapy-mediated apoptosis in apoptosis-resistant pancreatic adenocarcinoma AsPC-1 cells.


Subject(s)
Cyclohexanones/chemistry , Drug Resistance, Neoplasm/drug effects , Glutathione/antagonists & inhibitors , Lactoylglutathione Lyase/antagonists & inhibitors , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Line, Tumor , Cyclohexanones/pharmacology , Humans , Pancreatic Neoplasms/pathology , Structure-Activity Relationship
8.
J Am Chem Soc ; 126(38): 11808-9, 2004 Sep 29.
Article in English | MEDLINE | ID: mdl-15382912

ABSTRACT

The first catalytic enantioselective Reissert reaction of pyridine derivatives that affords products with excellent regio- and enantioselectivity is described. The key for success is the development of new Lewis acid-Lewis base bifunctional asymmetric catalysts containing an aluminum as a Lewis acid and sulfoxides or phosphine sulfides as a Lewis base. These reactions are useful for the synthesis of a variety of chiral piperidine subunits, and catalytic enantioselective formal synthesis of CP-293,019, a selective D4 receptor antagonist, was achieved. Preliminary mechanistic studies indicated that both sulfoxides and phosphine sulfides can activate TMSCN as a Lewis base. In addition, the sulfoxides with appropriate stereochemistry might stabilize a highly enantioselective bimetallic complex (a presumed active catalyst) through internal coordination to aluminum.


Subject(s)
Isoquinolines/chemistry , Piperidines/chemical synthesis , Pyridines/chemical synthesis , Quinolines/chemistry , Aluminum/chemistry , Catalysis , Naphthols/chemistry , Oxides/chemistry , Phosphines/chemistry , Piperidines/chemistry , Pyrazines/chemical synthesis , Pyridines/chemistry , Pyrimidines/chemical synthesis , Stereoisomerism
10.
Nihon Hansenbyo Gakkai Zasshi ; 72(3): 271-3, 2003 Aug.
Article in Japanese | MEDLINE | ID: mdl-14598638

ABSTRACT

We report two cases of Hansen's disease. Case 1 was 71-year old Japanese man who developed left ulnar nerve palsy since 7 years ago, multiple erythema on his body since 2-3 years ago, and erythematous nodules on his face since 3 months ago. He had no history of living outside Ibaraki prefecture. The clinical feature, the skin biopsy, laboratory data showed that he had borderline lepromatous leprosy. He was treated with multi-drug therapy which was effective and was stopped 3 years after the bacterial index showed negative. Ten months later, erythema on his body and face appeared and the therapy was restarted. Case 2 was 68-year old Japanese man who developed 5 cm of nummular erythema with slight numbness on his right forearm since 3 months ago. He had lived in Brazil since he was 24 to 64 years old. The skin biopsy showed epithelioid cell granuloma in the dermis involving vessels and nerves. Polymerase chain reaction test showed the M.leprae DNA, and he was diagnosed as indeterminate leprosy. He was treated with dapson and rifampicin and 2 months later, erythema and numbness disappeared.


Subject(s)
Leprostatic Agents/therapeutic use , Leprosy/diagnosis , Aged , Dapsone/therapeutic use , Drug Therapy, Combination , Humans , Leprosy/drug therapy , Leprosy/pathology , Male , Recurrence , Rifampin/therapeutic use , Treatment Outcome
12.
Exp Dermatol ; 12(4): 412-7, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12930297

ABSTRACT

We studied the expression of angiogenic factors (vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor and hepatocyte growth factor) in cutaneous neurofibroma samples from patients with neurofibromatosis-1. Immunohistochemical staining and the reverse transcribed polymerase chain reaction (RT-PCR) method demonstrated that vascular endothelial and basic fibroblast growths factor are highly expressed in neurofibroma cells at both the protein and mRNA level. These data suggest that vascular endothelial and basic fibroblast growth factors may contribute to both the angiogenesis and hypervascularity of neurofibromas.


Subject(s)
Angiogenic Proteins/metabolism , Neurofibroma/metabolism , Skin Neoplasms/metabolism , Angiogenic Proteins/genetics , Base Sequence , DNA, Complementary/genetics , Fibroblast Growth Factor 2/genetics , Fibroblast Growth Factor 2/metabolism , Hepatocyte Growth Factor/genetics , Hepatocyte Growth Factor/metabolism , Humans , Neurofibroma/genetics , Neurofibromatosis 1/genetics , Neurofibromatosis 1/metabolism , Neurofibromatosis 2/genetics , Neurofibromatosis 2/metabolism , Proto-Oncogene Proteins c-sis/genetics , Proto-Oncogene Proteins c-sis/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Skin Neoplasms/genetics , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...